Form 4: Verrica Pharmaceuticals Executive Acquires Shares and Options
SEC Form 4 Filing
Gary Goldenberg, Chief Medical Officer of Verrica Pharmaceuticals, reports acquisition of shares and stock options.
Summary
- Gary Goldenberg, the Chief Medical Officer of Verrica Pharmaceuticals, filed a Form 4 disclosing changes in beneficial ownership.
- On March 15, 2024, Goldenberg acquired 40,000 shares of common stock as a restricted stock unit (RSU) award.
- These RSUs will vest in equal annual installments on March 15 of 2025, 2026, 2027, and 2028, contingent upon continuous service.
- Additionally, Goldenberg acquired options to purchase 80,000 shares of common stock at an exercise price of $4.80.
- 25% of these options will vest on March 15, 2025, with the remaining options vesting monthly over the subsequent three years, also subject to continuous service.
- Following these transactions, Goldenberg directly owns 126,257 shares of Verrica Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to an executive, which is neither overwhelmingly positive nor negative.
Positives
- The acquisition of shares and options by a key executive could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Executive compensation in the pharmaceutical industry often includes stock options and restricted stock units to align management's interests with those of shareholders and incentivize long-term value creation.
Comparison to Industry Standards
- Stock option grants and RSU awards are common compensation practices in the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and exercise prices are generally structured to incentivize long-term performance and retention.
Stakeholder Impact
- The acquisition of shares and options by a key executive could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of transaction: Acquisition of shares and stock options. |
| 03/15/2025 | First vesting date for both RSUs and stock options. |
| 03/15/2026 | Second vesting date for RSUs. |
| 03/15/2027 | Third vesting date for RSUs. |
| 03/15/2028 | Final vesting date for RSUs. |
| 03/15/2034 | Expiration date for the employee stock options. |
| 03/19/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.